Smith & Nephew plc Price Target Increased to GBX 890 by Analysts at Credit Suisse (SN)
Equities researchers at Credit Suisse increased their price objective on shares of Smith & Nephew plc (LON:SN) from GBX 865 ($14.69) to GBX 890 ($15.11) in a research report issued on Wednesday. The firm currently has a “neutral” rating on the stock. Credit Suisse’s price objective points to a potential downside of 14.35% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Friday, July 25th. They now have a GBX 1,160 ($19.70) price target on the stock. Separately, analysts at BNP Paribas reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Thursday, July 24th. They now have a GBX 1,250 ($21.23) price target on the stock. Finally, analysts at Panmure Gordon reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Wednesday, July 23rd. They now have a GBX 975 ($16.56) price target on the stock. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 969 ($16.45).
Shares of Smith & Nephew plc (LON:SN) traded down 0.28% on Wednesday, hitting GBX 1039.0665. The stock had a trading volume of 1,589,132 shares. Smith & Nephew plc has a 1-year low of GBX 737.50 and a 1-year high of GBX 1136.00. The stock has a 50-day moving average of GBX 1046. and a 200-day moving average of GBX 955.9. The company’s market cap is £9.279 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.